A Phase 4 interventional study of Praluent in Heterozygous Familial Hypercholesterolemia and Non-familial Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Terminated at 124 sites in 6 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-06-15.
Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 5 in phase 4, and was the 40th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,389 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 4, and was the 12th registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to evaluate the long term safety of PRALUENT in participants with heterozygous familial hypercholesterolemia (heFH) or non-familial hypercholesterolemia (FH) participants at high or very high cardiovascular risk who completed the neurocognitive function study R727-CL-1532 (NCT02957682).
The secondary objectives of the study were:
Key Inclusion Criteria:
Participants randomized into the neurocognitive function study (R727-CL-1532) who completed treatment and the end of study (EOS) visit with no premature or permanent discontinuation of study drug.
Key Exclusion Criteria:
Note: Other inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Praluent
Subcutaneous (SC) administration
Also known as: Alirocumab, REGN727, SAR236553
Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 Weeks
An AE is any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. AEs include serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of special interest (AESI). AESI include local injection site reactions, general allergic events, elevated alanine aminotransferase (ALT) levels greater than or equal to (≥) 3 upper limit normal (ULN) (if baseline is less than (\<) ULN)/ALT ≥2 x ULN (if baseline ≥ ULN), neurologic events, neurocognitive events (according to Customized Medical Dictionary for Regulatory Activities \[MedDRA\] Query \[CMQ\] by Sponsor grouping and CMQ by FDA grouping), cataract, new onset diabetes (NOD), hepatic disorders, and diabetes mellitus (DM)/diabetic complications.
Time frame: After first administration of study drug through the last dose of study drug plus 2 weeks, up to 80 weeks
Calculated Low-density Lipoprotein Cholesterol (LDL-C) Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Percent Change in LDL-C From Baseline Over Time
Time frame: Up to week 72
Total Cholesterol (Total-C) Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Percent Change From Baseline in Total-C Over Time
Time frame: Up to week 72
Lipoprotein a (Lp(a)) Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Percent Change From Baseline in Lp(a) Over Time
Time frame: Up to week 72
Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Percent Change From Baseline in Non-HDL-C Over Time
Time frame: Up to week 72
High-density Lipoprotein Cholesterol (HDL-C) Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Percent Change From Baseline in HDL-C Over Time
Time frame: Up to week 72
Fasting Triglycerides (TGs) Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Percent Change From Baseline in Fasting TGs Over Time
Time frame: Up to week 72
Apolipoprotein B (Apo B) Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Percent Change From Baseline in Apo B Over Time
Time frame: Up to week 72
Apolipoprotein-A1 (Apo A1) Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Percent Change From Baseline in Apo A1 Over Time
Time frame: Up to week 72
Gonadal Hormone (Follicle Stimulating Hormone [FSH] and Luteinizing Hormone [LH]) Values for Female Participants From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Change From Baseline in Gonadal Hormones (FSH and LH) for Female Participants Over Time
Time frame: Up to week 72
Gonadal (FSH and LH) Hormone Values for Male Participants From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Change From Baseline in Gonadal Hormones (FSH and LH) for Male Participants Over Time
Time frame: Up to week 72
Gonadotropin (Estradiol) Values for Female Participants From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Change From Baseline in Gonadotropins (Estradiol) for Female Participants Over Time
Time frame: Up to week 72
Gonadotropin (Testosterone) Values for Male Participants From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Change From Baseline in Gonadotropins (Testosterone) for Male Participants Over Time
Time frame: Up to week 72
Alanine Aminotransferase Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Change From Baseline in Alanine Aminotransferase Over Time
Time frame: Up to week 72
Aspartate Aminotransferase Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Change From Baseline in Aspartate Aminotransferase Over Time
Time frame: Up to week 72
Alkaline Phosphatase Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Change From Baseline in Alkaline Phosphatase Over Time
Time frame: Up to week 72
Total Bilirubin Values From Baseline Over Time
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
Time frame: Up to week 72
Change From Baseline in Total Bilirubin Over Time
Time frame: Up to week 72
The 1389 participants who completed double-blind treatment and the end-of-study (EOS) visit in R727-CL-1532 (NCT02957682) signed consent and were screened for this open-label study (EOS visit corresponded to day 1/visit 1 of this study).
| Milestone | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Started | 1385 |
| Completed | 0 |
| Not completed | 1385 |
| Withdrew: Adverse event | 9 |
| Withdrew: Protocol became inconvenient to participate | 1 |
| Withdrew: Physician decision | 4 |
| Withdrew: Study terminated by sponsor | 1350 |
| Withdrew: Participant moved | 5 |
| Withdrew: Participant withdrew consent | 10 |
| Withdrew: Related to imp administration | 1 |
| Withdrew: Not disclosed | 5 |
An AE is any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. AEs include serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of special interest (AESI). AESI include local injection site reactions, general allergic events, elevated alanine aminotransferase (ALT) levels greater than or equal to (≥) 3 upper limit normal (ULN) (if baseline is less than (\<) ULN)/ALT ≥2 x ULN (if baseline ≥ ULN), neurologic events, neurocognitive events (according to Customized Medical Dictionary for Regulatory Activities \[MedDRA\] Query \[CMQ\] by Sponsor grouping and CMQ by FDA grouping), cataract, new onset diabetes (NOD), hepatic disorders, and diabetes mellitus (DM)/diabetic complications.
| Participants | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Any treatment emergent adverse event (TEAE) | 568 |
| Any treatment emergent serious adverse event (SAE) | 89 |
| Any TEAE leading to death | 5 |
| Any TEAE leading to permanent treatment discontinuation | 9 |
| Any neurocognitive disorders TEAE (by Sponsor CMQ) | 4 |
| Any neurocognitive disorders TEAE (by FDA CMQ) | 0 |
| Any NOD; # analyzed = # of participants w/out diabetes at baseline | 15 |
| Any hepatic disorders TEAE | 14 |
| Any neurological TEAE | 15 |
| Any general allergic TEAE | 25 |
| At least one treatment-emergent injection site reaction | 22 |
| Any cataract TEAE | 5 |
| Any elevated ALT ≥3 ULN | 1 |
| Any DM/diabetic complications TEAE; # analyzed = # of participants w/diabetes at baseline | 41 |
| Any DM/diabetic complications TEAE; # analyzed = # of participants w/out diabetes at baseline | 3 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| Milligrams per decilitre (mg/dL) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 117.8 ± 40.67 |
| Week 8 | 58.9 ± 37.31 |
| Week 12 | 63.6 ± 40.79 |
| Week 24 | 56.2 ± 36.59 |
| Week 48 | 56.8 ± 36.13 |
| Week 72 | 52.2 ± 38.80 |
| Percent Change | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -48.74 ± 31.121 |
| Week 12 | -44.64 ± 35.338 |
| Week 24 | -50.75 ± 30.249 |
| Week 48 | -52.35 ± 27.929 |
| Week 72 | -51.21 ± 32.742 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| mg/dL | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 199.5 ± 48.88 |
| Week 8 | 139.5 ± 44.76 |
| Week 12 | 145.0 ± 48.68 |
| Week 24 | 137.3 ± 44.18 |
| Week 48 | 139.5 ± 44.53 |
| Week 72 | 131.7 ± 43.25 |
| Percent Change | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -28.68 ± 20.158 |
| Week 12 | -25.99 ± 23.058 |
| Week 24 | -29.98 ± 20.930 |
| Week 48 | -30.89 ± 21.004 |
| Week 72 | -31.55 ± 22.238 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| mg/dL | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 39.7 ± 47.86 |
| Week 8 | 35.0 ± 41.99 |
| Week 12 | 32.7 ± 39.42 |
| Week 24 | 33.9 ± 42.54 |
| Week 48 | 38.6 ± 50.66 |
| Week 72 | 40.4 ± 56.47 |
| Percent Change | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -12.69 ± 35.452 |
| Week 12 | 10.63 ± 228.659 |
| Week 24 | -6.80 ± 110.827 |
| Week 48 | -7.89 ± 116.831 |
| Week 72 | -22.23 ± 28.233 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| mg/dL | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 152.4 ± 48.81 |
| Week 8 | 88.5 ± 43.54 |
| Week 12 | 94.3 ± 48.77 |
| Week 24 | 87.3 ± 43.56 |
| Week 48 | 88.9 ± 44.25 |
| Week 72 | 80.9 ± 42.67 |
| Percent Change | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -40.35 ± 27.470 |
| Week 12 | -36.89 ± 29.567 |
| Week 24 | -41.47 ± 26.763 |
| Week 48 | -42.33 ± 28.728 |
| Week 72 | -43.28 ± 29.534 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| mg/dL | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 47.1 ± 13.92 |
| Week 8 | 51.0 ± 14.82 |
| Week 12 | 50.6 ± 13.95 |
| Week 24 | 49.9 ± 14.80 |
| Week 48 | 50.5 ± 14.66 |
| Week 72 | 50.8 ± 14.61 |
| Percent Change | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | 10.54 ± 22.735 |
| Week 12 | 10.33 ± 21.933 |
| Week 24 | 8.53 ± 21.824 |
| Week 48 | 9.81 ± 23.690 |
| Week 72 | 9.24 ± 21.505 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| mg/dL | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 179.2 ± 146.51 |
| Week 8 | 154.8 ± 113.05 |
| Week 12 | 162.2 ± 182.00 |
| Week 24 | 169.3 ± 161.45 |
| Week 48 | 171.1 ± 131.35 |
| Week 72 | 156.9 ± 65.21 |
| Percent Change | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -4.68 ± 49.230 |
| Week 12 | -4.29 ± 40.748 |
| Week 24 | 0.42 ± 54.118 |
| Week 48 | 1.54 ± 69.156 |
| Week 72 | -5.97 ± 41.440 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| mg/dL | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 103.8 ± 27.25 |
| Week 8 | 62.5 ± 27.63 |
| Week 12 | 68.0 ± 31.32 |
| Week 24 | 61.5 ± 26.20 |
| Week 48 | 63.7 ± 26.40 |
| Week 72 | 58.5 ± 25.82 |
| Percent Change | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -36.51 ± 34.460 |
| Week 12 | -34.48 ± 27.905 |
| Week 24 | -38.16 ± 24.867 |
| Week 48 | -37.93 ± 23.767 |
| Week 72 | -39.04 ± 26.383 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| mg/dL | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 145.3 ± 24.95 |
| Week 8 | 148.5 ± 24.73 |
| Week 12 | 149.4 ± 25.38 |
| Week 24 | 150.7 ± 26.36 |
| Week 48 | 152.6 ± 25.96 |
| Week 72 | 151.4 ± 26.03 |
| Percent Change | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | 5.07 ± 13.385 |
| Week 12 | 2.99 ± 13.638 |
| Week 24 | 5.35 ± 14.108 |
| Week 48 | 4.77 ± 13.836 |
| Week 72 | 1.21 ± 13.170 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| International units per litre (IU/L) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| FSH Baseline | 57.948 ± 26.7383 |
| FSH Week 8 | 59.264 ± 24.7912 |
| FSH Week 12 | 54.279 ± 23.9923 |
| FSH Week 24 | 57.664 ± 25.9830 |
| FSH Week 48 | 56.529 ± 25.1408 |
| FSH Week 72 | 58.600 ± 24.5205 |
| LH Baseline | 30.155 ± 13.1090 |
| LH Week 8 | 33.794 ± 14.4459 |
| LH Week 12 | 30.779 ± 13.0946 |
| LH Week 24 | 31.260 ± 13.7344 |
| LH Week 48 | 29.585 ± 13.9792 |
| LH Week 72 | 29.248 ± 11.0829 |
| IU/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| FSH Week 8 | -0.765 ± 12.0083 |
| FSH Week 12 | -0.984 ± 12.1584 |
| FSH Week 24 | -0.575 ± 8.7780 |
| FSH Week 48 | -0.877 ± 15.9972 |
| FSH Week 72 | -1.861 ± 8.6119 |
| LH Week 8 | 2.730 ± 8.2258 |
| LH Week 12 | 1.882 ± 8.2884 |
| LH Week 24 | 0.939 ± 6.3694 |
| LH Week 48 | 0.367 ± 8.5631 |
| LH Week 72 | 0.222 ± 6.8910 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| International units per litre (IU/L) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| FSH Baseline | 8.006 ± 7.4451 |
| FSH Week 8 | 7.959 ± 7.5500 |
| FSH Week 12 | 7.766 ± 6.8204 |
| FSH Week 24 | 8.268 ± 8.1355 |
| FSH Week 48 | 9.597 ± 11.2138 |
| FSH Week 72 | 10.005 ± 13.2973 |
| LH Baseline | 6.500 ± 4.2832 |
| LH Week 8 | 7.094 ± 4.7226 |
| LH Week 12 | 6.688 ± 4.4079 |
| LH Week 24 | 6.931 ± 4.8597 |
| LH Week 48 | 7.677 ± 6.5478 |
| LH Week 72 | 8.173 ± 8.9083 |
| IU/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| FSH Week 8 | 0.285 ± 3.7264 |
| FSH Week 12 | -0.598 ± 4.1076 |
| FSH Week 24 | 0.331 ± 6.0522 |
| FSH Week 48 | 0.960 ± 10.3803 |
| FSH Week 72 | 2.458 ± 13.4730 |
| LH Week 8 | 0.535 ± 2.4847 |
| LH Week 12 | -0.136 ± 3.2638 |
| LH Week 24 | 0.582 ± 4.4964 |
| LH Week 48 | 1.015 ± 6.6344 |
| LH Week 72 | 1.964 ± 9.3028 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| picomoles per litre (pmol/L) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 55.589 ± 80.8238 |
| Week 8 | 58.676 ± 69.0119 |
| Week 12 | 59.673 ± 74.7587 |
| Week 24 | 64.304 ± 103.8955 |
| Week 48 | 64.503 ± 102.1595 |
| Week 72 | 57.926 ± 67.1795 |
| pmol/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | 4.272 ± 77.1561 |
| Week 12 | 9.262 ± 73.1050 |
| Week 24 | 7.869 ± 78.4151 |
| Week 48 | 11.763 ± 97.5350 |
| Week 72 | 9.569 ± 38.0952 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| nanomoles per litre (nmol/L) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 13.4370 ± 6.36321 |
| Week 8 | 14.5802 ± 5.99821 |
| Week 12 | 14.2443 ± 6.77070 |
| Week 24 | 13.5818 ± 6.11269 |
| Week 48 | 13.4798 ± 7.04977 |
| Week 72 | 12.7538 ± 6.37408 |
| nmol/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | 0.6030 ± 4.46401 |
| Week 12 | 0.7965 ± 4.74765 |
| Week 24 | 0.1946 ± 5.89220 |
| Week 48 | 0.0498 ± 6.34201 |
| Week 72 | 1.2569 ± 5.29335 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| U/L (Units per Liter) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 0.516 ± 0.3218 |
| Week 8 | 0.468 ± 0.2745 |
| Week 12 | 0.505 ± 0.4940 |
| Week 24 | 0.493 ± 0.2851 |
| Week 48 | 0.533 ± 0.3267 |
| Week 72 | 0.468 ± 0.2340 |
| U/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -0.025 ± 0.3006 |
| Week 12 | 0.009 ± 0.5189 |
| Week 24 | -0.036 ± 0.3294 |
| Week 48 | -0.027 ± 0.3052 |
| Week 72 | -0.062 ± 0.1872 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| U/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 0.553 ± 0.2516 |
| Week 8 | 0.520 ± 0.2536 |
| Week 12 | 0.527 ± 0.2698 |
| Week 24 | 0.544 ± 0.3071 |
| Week 48 | 0.565 ± 0.2773 |
| Week 72 | 0.556 ± 0.2256 |
| U/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -0.022 ± 0.2856 |
| Week 12 | -0.017 ± 0.3004 |
| Week 24 | -0.013 ± 0.2901 |
| Week 48 | -0.019 ± 0.2390 |
| Week 72 | -0.037 ± 0.1730 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| U/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 0.601 ± 0.1865 |
| Week 8 | 0.635 ± 0.2151 |
| Week 12 | 0.605 ± 0.1865 |
| Week 24 | 0.602 ± 0.2012 |
| Week 48 | 0.602 ± 0.2657 |
| Week 72 | 0.553 ± 0.1678 |
| U/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | 0.009 ± 0.1371 |
| Week 12 | 0.013 ± 0.1203 |
| Week 24 | 0.006 ± 0.1152 |
| Week 48 | 0.024 ± 0.2333 |
| Week 72 | -0.011 ± 0.1029 |
The baseline value was defined as the last available value before the first dose of double-blind study treatment in study R727-CL-1532 (NCT02957682)
| micromoles per litre (umol/L) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Baseline | 10.76 ± 4.736 |
| Week 8 | 10.01 ± 4.123 |
| Week 12 | 10.26 ± 4.758 |
| Week 24 | 10.41 ± 4.922 |
| Week 48 | 10.06 ± 4.503 |
| Week 72 | 8.82 ± 3.770 |
| umol/L | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Week 8 | -0.37 ± 3.120 |
| Week 12 | -0.44 ± 3.854 |
| Week 24 | -0.48 ± 3.962 |
| Week 48 | -0.05 ± 3.991 |
| Week 72 | 0.71 ± 2.152 |
Collected over Adverse events were recorded from the time of signed informed consent until the end of study, up to 80 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alirocumab 75 Q2W/Up150 Q2W | 5/1,385 (0.4%) | 89/1,385 (6.4%) | 0/1,385 (0%) |
| Event | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Angina unstableCardiac disorders | 10/1385 |
| Angina pectorisCardiac disorders | 8/1385 |
| Atrial fibrillationCardiac disorders | 6/1385 |
| Acute myocardial infarctionCardiac disorders | 5/1385 |
| PneumoniaInfections and infestations | 4/1385 |
| Chest painGeneral disorders | 3/1385 |
| Acute left ventricular failureCardiac disorders | 2/1385 |
| Cardiac failure congestiveCardiac disorders | 2/1385 |
| Coronary artery diseaseCardiac disorders | 2/1385 |
| Cerebrovascular accidentNervous system disorders | 2/1385 |
Demographic and other baseline characteristics were based on the data collected in R727-CL-1532 (NCT02957682). The baseline value was generally defined as the last available value before the first dose of double-blind study treatment in that study.
| Age, Continuous(Years) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Mean | 64.6 ± 8.63 |
| Sex: Female, Male(Participants) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Female | 527 |
| Male | 858 |
| Ethnicity (NIH/OMB)(Participants) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| Hispanic or Latino | 10 |
| Not Hispanic or Latino | 1372 |
| Unknown or Not Reported | 3 |
| Race/Ethnicity, Customized(Participants) | Alirocumab 75 Q2W/Up150 Q2W |
|---|---|
| White | 1178 |
| Black or African American | 81 |
| Asian | 7 |
| American Indian or Alaska Native | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Other | 118 |
Showing the first 100 of 124 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Apr 2020, 18 months.
Results were first posted in Jun 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab